Therapeutic vaccination in primary HIV infection, the Quest trial.
Perrin
Luc
L
Division of Infectious Diseases, University Hospital of Geneva, Geneva, Switzerland. luc.perrin@hcuge.ch
D016915:AIDS Vaccines / Q000235:genetics / Q000627:therapeutic use*; D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000473:pathology; D002219:Carbamates; D003131:Combined Modality Therapy; D003673:Defective Viruses / Q000235:genetics / Q000276:immunology; D015224:Dideoxynucleosides / Q000627:therapeutic use; D005663:Furans; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D006801:Humans; D016233:Immunotherapy, Active; D019259:Lamivudine / Q000627:therapeutic use; D018655:Lymphocyte Count; D013449:Sulfonamides / Q000627:therapeutic use; D016176:T-Lymphocyte Subsets / Q000276:immunology; D014611:Vaccination; D014616:Vaccinia virus / Q000235:genetics / Q000276:immunology; D019562:Viral Load; D014765:Viral Vaccines / Q000276:immunology; D014766:Viremia / Q000188:drug therapy / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D015215:Zidovudine / Q000627:therapeutic use; D000099227:Abacavir
D016915:AIDS Vaccines; D019380:Anti-HIV Agents; D002219:Carbamates; D015224:Dideoxynucleosides; D005663:Furans; D019259:Lamivudine; D013449:Sulfonamides; D014765:Viral Vaccines; D015215:Zidovudine; D000099227:Abacavir; C468116:ALVAC-HIV vCP1452; C105086:remune; C095108:amprenavir